Description
Chronic lung diseases such as chronic obstructive pulmonary disease (COPD), bronchiectasis and asthma are highly heterogeneous in their aetiology, phenotypes, disease pathophysiology and clinical outcomes. This heterogeneity makes it challenging to develop effective treatments for all patients. “Stratified medicine” or “precision medicine” based on biomarkers have been proposed as a solution to address these complex issues but successes remain limited. In this presentation, I will focus on our recent studies in bronchiectasis and COPD where several promising biomarkers were discovered and validated using mass spectrometry. The importance of “proximity” sampling and “extreme phenotype” approach in biomarker discovery as well as the long-term follow up in clinical validation will be highlighted. Finally, I will argue that mass spectrometry will continue to play a pivotal role in the field of precision respiratory medicine and has the potential to revolutionize the diagnosis and treatment of chronic lung diseases.| Period | 3 Nov 2023 |
|---|---|
| Event title | Scottish Biological Mass Spectrometry Meeting |
| Event type | Conference |
| Location | Edinburgh, United KingdomShow on map |
| Degree of Recognition | National |